PE PEN Penumbra, Inc. 로딩 중... : 애널리스트의 강세 및 약세 의견

The acquisition of Penumbra is expected to close in H2 2026, adding to BSX's cardiovascular product portfolio and strengthening long-term growth.

The acquisition is on track to close, bringing a differentiated portfolio and a strong team to BSX.

Acquisition of Penumbra is expected to close in 2026, adding mechanical thrombectomy and neurovascular capabilities.

Stryker acknowledged its ischemic neurovascular business has been pressured for two years, with a new large-bore aspiration catheter only in early US launch, while hemorrhagic has overtaken market leadership — a mixed competitive signal for neurovascular rivals. — Competitors in ischemic stroke aspiration still have a window before Stryker's Broadway launch scales globally, while Stryker's hemorrhagic strength raises the bar in that segment.